Venus Remedies Ltd
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.83Venus Remedies Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits good solvency, driven by a strong equity position. Growth prospects appear promising, fueled by positive trends in operating profit, EPS, and asset expansion. Profitability, particularly regarding ROCE and ROA, is a notable strength. However, liquidity is a significant area of concern, reflecting challenges in meeting short-term obligations. Efficiency ratios also indicate potential operational bottlenecks. While coverage ratios are weak, the financial ratios present a moderate outlook, supported by cash EPS and book value per share. The company's future hinges on addressing its liquidity issues and improving operational efficiency to capitalize on its growth and profitability.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio4.20
- Profitability Ratio4.60
- Efficiency Ratio4.67
- Coverage Ratio2.00
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Health Score : 4.83Venus Remedies Ltd, operating in the Healthcare Services sector, showcases a mixed financial performance. The company exhibits good solvency, driven by a strong equity position. Growth prospects appear promising, fueled by positive trends in operating profit, EPS, and asset expansion. Profitability, particularly regarding ROCE and ROA, is a notable strength. However, liquidity is a significant area of concern, reflecting challenges in meeting short-term obligations. Efficiency ratios also indicate potential operational bottlenecks. While coverage ratios are weak, the financial ratios present a moderate outlook, supported by cash EPS and book value per share. The company's future hinges on addressing its liquidity issues and improving operational efficiency to capitalize on its growth and profitability.
Overall Valuation Score
P/E RATIO (TTM)
24.19
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
23.37
P/B RATIO
3.62
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
N/A
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1797.5 as on Jun 12, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth Score : 6.00The company exhibits strong growth in several key areas, including operating profit, EPS, and asset growth. However, the lack of revenue and net income growth suggests that these improvements are not translating into top-line performance. While profitability is increasing, the company needs to focus on driving revenue growth to achieve sustainable long-term expansion.
Revenue Growth RatePoor
Operating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 9.74 | -7.54 | 7.97 | 7.38 | 20.31 |
| Operating Profit Growth Rate | 14.81 | -3.23 | 0 | 6.67 | 129.69 |
| Earnings Per Share (EPS) Growth | -39.14 | -34.73 | 7.19 | 59.08 | 126.84 |
| Asset Growth Rate | 4.32 | 3.62 | 4.33 | 14.19 | 19.27 |
| Net Income Growth Rate | -33.87 | -34.15 | 3.7 | 60.71 | 128.89 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 4.20The company's financial ratios show a mixed performance. While capital expenditures are well-managed, adjusted EPS and dividend per share are low. Cash EPS and book value per share provide some support, but overall, there is room for improvement in key financial metrics to enhance investor confidence and long-term financial health.
Adjusted Earnings Per Share (Adjusted EPS)PoorCash Earnings Per Share (Cash EPS)WeakBook Value Per ShareWeakDividend Per Share (DPS)PoorCapital Expenditures (CapEx)Excellent| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 31.54 | 20.77 | 21.54 | 28.46 | 79.23 |
| Cash Earnings Per Share (Cash EPS) | 57.69 | 45.38 | 41.54 | 52.31 | 99.23 |
| Book Value Per Share | 338.46 | 353.85 | 374.62 | 431.54 | 510 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 10 |
| Capital Expenditures (CapEx) | 0 | 8 | 14 | 18 | 38 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 4.60The company demonstrates average profitability. Strong ROCE and ROA are offset by low gross profit, operating, and net margins. While the company is generating good returns on its capital and assets, it needs to improve its margins to enhance overall profitability. Addressing cost management and pricing strategies can lead to better margin performance.
Gross Profit MarginPoorReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)Poor
Return on Assets (ROA)GoodOperating MarginPoorNet MarginPoor| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 4.69 | 5.07 | 5.7 | 6.41 | 15.71 |
| Return on Capital Employed (ROCE) | 8 | 8 | 9 | 11 | 22 |
| Return on Equity (ROE) | 9.32 | 5.87 | 5.75 | 8.02 | 15.54 |
| Return on Assets (ROA) | 10.69 | 9.98 | 9.57 | 8.94 | 17.21 |
| Operating Margin | 10.39 | 10.87 | 10.07 | 10 | 19.09 |
| Net Margin | 6.87 | 4.89 | 4.7 | 7.03 | 13.38 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 4.67The company's efficiency is average. While the Days Sales in Inventory and Receivable Days are well-managed, the turnover ratios for fixed assets, inventory, receivables, and capital are low. This suggests potential inefficiencies in asset utilization and working capital management. Addressing these areas could lead to improved profitability and operational effectiveness.
Fixed Asset Turnover RatioPoorInventory Turnover RatioPoorReceivables Turnover RatioPoorDays Sales in Inventory RatioExcellentReceivable DaysExcellentCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.48 | 2.56 | 2.72 | 2.79 | 3.32 |
| Inventory Turnover Ratio | 4.63 | 4.26 | 4.65 | 5.41 | 5.66 |
| Receivables Turnover Ratio | 16.82 | 9.52 | 7.59 | 6.67 | 7.16 |
| Days Sales in Inventory Ratio | 78.83 | 85.68 | 78.49 | 67.47 | 64.49 |
| Receivable Days | 21.7 | 38.34 | 48.09 | 54.72 | 50.98 |
| Capital Turnover Ratio | 1.25 | 1.11 | 1.13 | 1.14 | 1.14 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 2.00The company's coverage ratios are weak, particularly regarding interest coverage. This suggests potential difficulties in meeting interest obligations. The absence of equity dividend coverage raises concerns about investor returns. Improving profitability and managing debt can enhance these ratios.
Interest Coverage RatioPoorEquity Dividend Coverage RatioPoor| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | N/A | N/A | N/A | N/A | N/A |
| Equity Dividend Coverage Ratio | 7.69 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00The company displays excellent solvency, primarily due to its strong equity position and minimal debt. This indicates a low risk of financial distress and a stable capital structure. The absence of debt provides financial flexibility and reduces vulnerability to economic downturns. The company's ability to maintain this position will be crucial for long-term stability and growth.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.08 | 0.08 | 0.07 | 0 | 0.02 |
| Debt to Equity Ratio | 0.09 | 0.09 | 0.08 | 0 | 0.02 |
| Equity Ratio | 0.92 | 0.92 | 0.93 | 1 | 0.98 |
| Debt To Asset Ratio | 0.07 | 0.06 | 0.06 | 0 | 0.01 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 2.00The liquidity position is weak, indicating potential difficulties in meeting short-term obligations. Low current, quick, and cash ratios suggest a struggle to convert assets into cash quickly. While a low operating cash flow ratio raises concerns about the company's ability to generate cash from its operations, the company needs to improve its short term obligations.
Current RatioPoorQuick RatioPoorCash RatioPoorOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.34 | 3.66 | 2.43 | 1.87 |
| Quick Ratio | 1.86 | 2.16 | 2.44 | 1.78 | 1.15 |
| Cash Ratio | 0.49 | 0.53 | 0.68 | 0.52 | 0.17 |
| Operating Cash Flow Ratio | 0.41 | 0.36 | 0.37 | 0.56 | 0.88 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 32.75 | Overvalued | 58.00 | 6.42 | 43.00 |
| 2 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 3 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.87 | Neutral | 98.00 | 43.88 | 88.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 39.09 | Overvalued | 73.00 | 67.39 | 48.00 |
| 5 | Syncom Formulations (India) Ltd | 6.92 | 17.26 | Undervalued | 77.00 | 0.81 | 76.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kilitch Drugs (India) Ltd | 6.61 | 21.17 | Neutral | 37.00 | 9.27 | 30.00 |
| 8 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 9 | SMS Lifesciences India Ltd | 6.59 | 21.78 | Neutral | 45.00 | 70.68 | 19.00 |
| 10 | Hester Biosciences Ltd | 6.54 | 31.47 | Neutral | 87.00 | 61.24 | 57.00 |
| 11 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 12 | Infinium Pharmachem Ltd | 6.42 | 26.49 | Neutral | 22.00 | 6.43 | 14.00 |
| 13 | Sakar Healthcare Ltd | 5.81 | 58.09 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 14 | Medicamen Biotech Ltd | 5.73 | 31.76 | Neutral | 20.00 | 6.94 | 10.00 |
| 15 | Albert David Ltd | 5.63 | -272.76 | Neutral | 5.00 | -2.62 | -1.00 |
| 16 | Remus Pharmaceuticals Ltd | 5.31 | 26.36 | Neutral | 57.00 | 20.97 | 46.00 |
| 17 | Ind-Swift Laboratories Ltd | 4.95 | 35.36 | Neutral | 45.00 | 4.89 | 41.00 |
| 18 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 19 | Wanbury Ltd | 4.65 | 28.05 | Neutral | 88.00 | 18.93 | 43.00 |
| 20 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Balanced ManagementThe management effectiveness of Venus Remedies Ltd. shows a mixed performance. The company has demonstrated strong revenue expansion and has significantly reduced its borrowings, indicating improved financial health. However, operational efficiency is inconsistent, as reflected in the fluctuating operating profit margins and a decline in profit growth over the past three years. Promoter holding has remained consistent, suggesting alignment with shareholders.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Sales Growth (5Y) | 14% | Strong revenue expansion noted. |
| Debt Reduction | Significant reduction in borrowings | Indicates improved financial health. | |
| CONS | OPM Volatility | Fluctuating OPM % quarterly | Operational efficiency is inconsistent. |
| Profit Growth (3Y) | -1% | Profitability growth is weak. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsAverageFinancial Health & PrudenceGoodShareholding & Ownership StructureGoodFinancial Performance & Growth
The financial performance and growth of Venus Remedies Ltd. present a mixed trend. The compounded sales growth over 5 years is 14%, indicating a positive trajectory in revenue. However, the compounded profit growth over 3 years is -1%, suggesting challenges in maintaining profitability. Quarterly sales have been volatile, with YOY sales growth fluctuating significantly. The OPM% has also varied, indicating inconsistency in operational efficiency. While sales have grown, the ability to translate this into consistent profit remains a concern.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Compounded Sales Growth | N/A | N/A | N/A | N/A | N/A | 9% | | Compounded Profit Growth | N/A | N/A | N/A | N/A | N/A | 39% |
Capital Efficiency & Returns
Venus Remedies Ltd.'s capital efficiency and returns present a mixed performance. The ROCE has improved to 11% in Mar 2025, indicating better utilization of capital. However, the ROE remains at 6.18%, which is relatively low. Cash Conversion Cycle has improved to 72 Days in Mar 2025, suggesting enhanced working capital management. Overall, while there are improvements in some areas, the returns on equity need enhancement.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | ROCE % | 5% | 1% | 8% | 8% | 9% | 11% |
Financial Health & Prudence
The financial health and prudence of Venus Remedies Ltd. show positive trends. The company has significantly reduced its borrowings over the years. The interest coverage ratio is strong as interest expenses are zero in recent years. The company has not been paying dividends. The debt-to-equity ratio suggests a manageable leverage position.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Borrowings | 318.33 | 305.67 | 45.67 | 42 | 41 | 2 |
Shareholding & Ownership Structure
The shareholding and ownership structure of Venus Remedies Ltd. indicate stability. The promoter holding has been consistently around 41.76%, suggesting confidence in the company. FII holding has increased slightly over the past few years, indicating growing interest from foreign institutional investors.
| Shareholding Pattern | Mar 2017 | Mar 2019 | Mar 2021 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Promoters | 37.51% | 37.51% | 35.89% | 41.76% | 41.76% |
| FIIs | 0.48% | 0.04% | 0.04% | 1.00% | 1.34% |
Balanced RiskThe risk assessment for Venus Remedies Ltd. reveals a moderate level of concern. While the company has shown improvements in debt management and working capital efficiency, inconsistencies in sales growth and OPM% signal operational vulnerabilities. The absence of dividends and fluctuating profitability add to the risk profile.
Off-balance sheet exposure quantificationAverageContingent liability evaluationAverageSegment performance volatilityAverageForeign exchange or interest rate exposureAverageRegulatory compliance cost trendsAverageOff-balance sheet exposure quantification
There is no specific data available on off-balance sheet exposure quantification.
Contingent liability evaluation
There is no specific data available on contingent liability evaluation.
Segment performance volatility
There is no specific data available on segment performance volatility.
Foreign exchange or interest rate exposure
There is no specific data available on foreign exchange or interest rate exposure.
Regulatory compliance cost trends
There is no specific data available on regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe